Are Counterfeit Ozempic Injections Putting Patients at Risk?

The Food and Drug Administration (FDA) has made a troubling discovery within the legitimate supply chain – thousands of counterfeit units of Ozempic injections have been seized. Although efforts are underway to test the seized drugs, some of these fake products may still be in circulation, posing potential risks to patients.

Manufactured by Novo Nordisk, a Danish pharmaceutical company, Ozempic has gained immense popularity for its weight loss benefits. However, the FDA is currently working with Novo Nordisk to assess the quality and safety of the seized counterfeit drugs. At present, no findings regarding their quality or safety have been announced.

The FDA has acknowledged the occurrence of five adverse events related to this specific lot of counterfeit Ozempic. Fortunately, these events were not serious and align with known common adverse reactions to authentic Ozempic, such as nausea, vomiting, diarrhea, abdominal pain, and constipation.

In light of this situation, the FDA is issuing a warning to various stakeholders, including wholesalers, pharmacies, healthcare practitioners, and patients, urging them to carefully inspect their product labels for counterfeit units and report any suspicious products to the agency. The counterfeit units can be identified by the lot number NAR0074 and serial number 430834149057.

It is important to note that even the needles in these counterfeit units are fake. The FDA has been unable to confirm whether these needles are sterile, thereby increasing the risk of infection for consumers.

To assist consumers in identifying the counterfeit products, the FDA has released photos showcasing examples of authentic and counterfeit Ozempic units.

Novo Nordisk has reported substantial sales, with over $24.5 billion in revenue during the first nine months of 2023. A significant portion of these sales is attributed to Ozempic, which has gained popularity not only for its approved use in lowering blood sugar levels for patients with Type 2 diabetes but also for its ability to curb food cravings through its active ingredient, semaglutide, as reported by the University of California-Davis.

It is important to note that while Ozempic has not been approved by the FDA for weight loss, another Novo Nordisk drug utilizing semaglutide, Wegovy, received FDA approval in 2021 for weight management.

Amidst concerns over counterfeit Ozempic injections, patient safety remains paramount. It is crucial for healthcare providers, patients, and stakeholders to remain vigilant, report any suspicious products, and await further updates and guidance from the FDA and Novo Nordisk to ensure the use of genuine and safe medications.